Geneuro Sa

Geneuro Sa company information, Employees & Contact Information

Explore related pages

Related company profiles:

GeNeuro is a biotechnology company developing innovative treatments against inflammatory and neurodegenerative disorders associated with Human Endogenous Retroviruses (HERVs). We are committed to fight the progression of disability in Multiple Sclerosis #FightMS and other neurodegenerative diseases #ALS #LongCOVID Our Community Guidelines: http://bit.ly/36y9YCE

Company Details

Employees
16
Founded
-
Phone
41227945085
Email
co****@****uro.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Looking for a particular Geneuro Sa employee's phone or email?

Geneuro Sa Questions

News

GeNeuro SA Postpones Publication of June 30, 2025 Half-Yearly Financial Report - Business Wire

GeNeuro SA Postpones Publication of June 30, 2025 Half-Yearly Financial Report Business Wire

GeNeuro Announces Approval of All Resolutions Proposed at Extraordinary General Meeting - Yahoo Finance

GeNeuro Announces Approval of All Resolutions Proposed at Extraordinary General Meeting Yahoo Finance

GeNeuro SA Announces the Liquidation of Its French Subsidiary GeNeuro Innovation SAS - Business Wire

GeNeuro SA Announces the Liquidation of Its French Subsidiary GeNeuro Innovation SAS Business Wire

GeNeuro SA Announces the Postponement of the Publication of the Company's 2024 Annual Results - Yahoo Finance

GeNeuro SA Announces the Postponement of the Publication of the Company's 2024 Annual Results Yahoo Finance

Geneuro SA Postpones Publication Of Half-Yearly Financial Report - TradingView

Geneuro SA Postpones Publication Of Half-Yearly Financial Report TradingView

Geneuro SA postpones publication of half-yearly financial report - MarketScreener

Geneuro SA postpones publication of half-yearly financial report MarketScreener

GeNeuro SA Announces the Extension of its Definitive Debt-Restructuring Moratorium - Business Wire

GeNeuro SA Announces the Extension of its Definitive Debt-Restructuring Moratorium Business Wire

GeNeuro SA Announces an Extraordinary Shareholders’ Meeting on June 30, 2025 - Yahoo Finance

GeNeuro SA Announces an Extraordinary Shareholders’ Meeting on June 30, 2025 Yahoo Finance

Geneuro SA Announces Extension Of Its Definitive Debt-Restructuring Moratorium - TradingView

Geneuro SA Announces Extension Of Its Definitive Debt-Restructuring Moratorium TradingView

Geneuro SA announces extension of its definitive Debt Restructuring moratorium - MarketScreener

Geneuro SA announces extension of its definitive Debt Restructuring moratorium MarketScreener

GeNeuro's long COVID trial fails, triggering layoffs and search for strategic alternatives - Fierce Biotech

GeNeuro's long COVID trial fails, triggering layoffs and search for strategic alternatives Fierce Biotech

Temelimab Proves Safe at Highest Dose for Multiple Sclerosis in Phase 2 Topline Data - NeurologyLive

Temelimab Proves Safe at Highest Dose for Multiple Sclerosis in Phase 2 Topline Data NeurologyLive

HERV-W ENV antigenemia and correlation of increased anti-SARS-CoV-2 immunoglobulin levels with post-COVID-19 symptoms - Frontiers

HERV-W ENV antigenemia and correlation of increased anti-SARS-CoV-2 immunoglobulin levels with post-COVID-19 symptoms Frontiers

SARS-CoV-2 induces human endogenous retrovirus type W envelope protein expression in blood lymphocytes and in tissues of COVID-19 patients - medRxiv

SARS-CoV-2 induces human endogenous retrovirus type W envelope protein expression in blood lymphocytes and in tissues of COVID-19 patients medRxiv

Will GeNeuro SA (GEM) stock benefit from mergers - 2025 Price Action Summary & Free Real-Time Volume Trigger Notifications - newser.com

Will GeNeuro SA (GEM) stock benefit from mergers - 2025 Price Action Summary & Free Real-Time Volume Trigger Notifications newser.com

GeNeuro secures EUR 5 million to advance post-COVID and neurodegenerative disease treatments - Greater Geneva Bern area

GeNeuro secures EUR 5 million to advance post-COVID and neurodegenerative disease treatments Greater Geneva Bern area

Antibodies Against Viral Protein Tied to Better Survival Rate in ALS - ALS News Today

Antibodies Against Viral Protein Tied to Better Survival Rate in ALS ALS News Today

SARS-CoV-2 induces human endogenous retrovirus type W envelope protein expression in blood lymphocytes and in tissues of COVID-19 patients - medRxiv

SARS-CoV-2 induces human endogenous retrovirus type W envelope protein expression in blood lymphocytes and in tissues of COVID-19 patients medRxiv

GeNeuro's experimental multiple sclerosis drug shows hints it may help treat COVID-19 - Fierce Biotech

GeNeuro's experimental multiple sclerosis drug shows hints it may help treat COVID-19 Fierce Biotech

Blocking Hidden Viral Protein Shows Promise for Treating Multiple Sclerosis - Labiotech.eu

Blocking Hidden Viral Protein Shows Promise for Treating Multiple Sclerosis Labiotech.eu

Servier drops GeNeuro’s multiple sclerosis drug after midphase miss - Fierce Biotech

Servier drops GeNeuro’s multiple sclerosis drug after midphase miss Fierce Biotech

Top Geneuro Sa Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant